Skip to main content

Table 4 Statistical comparison of pertinent clinical parameters between subtype IV patients treated with CAF and CMF adjuvant chemotherapy.

From: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization

 

Molecular Subtype IV breast Cancer

 

CAF

CMF

p value*

 

Patients (n = 22)

Patients (n = 17)

 

Age at diagnosis

    

0.464

< 50 yr

15

68.2%

14

82.4%

 

>= 50 yr

7

31.8%

3

17.6%

 

TNM Path T

    

0.612

1

3

13.6%

2

11.8%

 

2

19

86.4%

13

76.5%

 

3

0

0.0%

1

5.9%

 

4

0

0.0%

1

5.9%

 

TNM Path N

    

0.047

0

9

40.9%

11

64.7%

 

1

12

54.5%

3

17.6%

 

2

1

4.5%

2

11.8%

 

3

0

0.0%

1

5.9%

 

TNM Path M

    

0.436

0

22

100.0%

16

94.1%

 

1

0

0.0%

1

5.9%

 

Positive Lymph Nodes

   

0.067

0

9

40.9%

11

64.7%

 

1-3

12

54.5%

3

17.6%

 

4-9

1

4.5%

2

11.8%

 

TNM Stage

    

0.109

I

0

0.0%

2

11.8%

 

II

21

95.5%

12

70.6%

 

III

1

4.5%

2

11.8%

 

IV

0

0.0%

1

5.9%

 

Nuclear Grade

    

0.495

1

1

4.5%

0

0.0%

 

2

2

9.1%

0

0.0%

 

3

19

86.4%

17

100.0%

 

Post-op Radiation Rx

   

1.000

No

14

63.6%

11

64.7%

 

Yes

8

36.4%

6

35.3%

 
  1. *: p values were determined by Fisher's exact test.
  2. There was no difference in follow-up duration between two groups (median 9.0 vs. 7.5 years, p = 0.90 by Wilcoxon rank sum test).